Notices to creditors (MVL)
Graegis Pharmaceuticals Limited
In short: Graegis Pharmaceuticals Limited (company no. 13680871) entered members' voluntary liquidation, a solvent and planned closure, according to a Notices to creditors (MVL) notice published in The London Gazette on 12 October 2026. The office holder is James Hopkirk (IP No. 21150) of Kreston Reeves LLP, 2nd Floor Maritime Place, Quayside, Chatham Maritime, Kent, ME4 4QZ, appointed 30 September 2026. The company's business: research and experimental development on biotechnology, trading from C/O The Cambridge Partnership The Dorothy Hodgkin Building, Babraham, Cambridge, Cambridgeshire, CB22 3AT.
The liquidator of Graegis Pharmaceuticals Ltd announces final creditor claims and intends to distribute remaining funds to shareholders after a members’ voluntary liquidation.
Notice details
- Company
- GRAEGIS PHARMACEUTICALS LIMITED
- Company number
- 13680871
- Nature of business
- Research and experimental development on biotechnology
- Type of liquidation
- Members’ voluntary liquidation
- Registered office
- C/O The Cambridge Partnership The Dorothy Hodgkin Building, Babraham Research Campus, Cambridge, CB22 3FH
- Principal trading address
- C/O The Cambridge Partnership The Dorothy Hodgkin Building, Babraham, Cambridge, Cambridgeshire, CB22 3AT
- Liquidator
- James Hopkirk (IP No. 21150) of Kreston Reeves LLP, 2nd Floor Maritime Place, Quayside, Chatham Maritime, Kent, ME4 4QZ
- Date of appointment
- 30 September 2026
- Final date for submission
- 9 November 2026
- Contact
- Mansi Thawani, Kreston Reeves LLP, 01634 899800, [email protected]
What this notice means
A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress.
Read more: What is Liquidation?.
All notices for Graegis Pharmaceuticals Limited
3 Gazette notices on record for company no. 13680871, newest first. The full history, with last filed accounts, is on the Graegis Pharmaceuticals Limited company record.
- Appointment of liquidators (MVL) 12 Oct 2026
- Resolution for winding up (MVL) 12 Oct 2026
How does this notice affect you?
Choose what applies and we'll point you at the right next step.
A written-off invoice rarely stops at the company that failed. The supplier left short is often the next business in difficulty — and the earlier that's dealt with, the more options stay open. If GRAEGIS PHARMACEUTICALS LIMITED owed you money, it's worth checking where that leaves you.
Unpaid wages, holiday pay and statutory redundancy are claimed from the government's Redundancy Payments Service, not from K2. The insolvency practitioner named in this notice should send you a case reference — you'll need it to claim.
K2's founder has turned around UK businesses since 1990, and K2 has backed and restructured them since 2001, including buying trade and assets out of distress. These situations move in days rather than months, so if you're looking at GRAEGIS PHARMACEUTICALS LIMITED or something similar, start the conversation early.
A members' voluntary liquidation is a solvent, orderly closure — often part of retirement, a group restructure, or moving on to the next venture. K2's founder has advised UK company directors since 1990 on restructuring and what comes next. If that's on your horizon, talk to us.
Related guidance
Free, practical guides from K2 on what this kind of notice means for directors.
More liquidation notices
Frequently asked questions
Is Graegis Pharmaceuticals Limited in financial difficulty?
No — this is a solvent process. A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress. The London Gazette published a Notices to creditors (MVL) for Graegis Pharmaceuticals Limited (company no. 13680871) on 12 October 2026.
What does a Notices to creditors (MVL) mean?
A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress.
Who is dealing with the liquidation?
The office holder named in the notice: James Hopkirk (IP No. 21150) of Kreston Reeves LLP, 2nd Floor Maritime Place, Quayside, Chatham Maritime, Kent, ME4 4QZ, appointed 30 September 2026. Creditors, employees and anyone holding goods or money belonging to the company should contact them directly, quoting the company number.
Source: The London Gazette and Companies House. Contains public sector information licensed under the Open Government Licence v3.0. © Crown copyright. This page is provided by K2 Partners for information only and is not legal or financial advice.